ProCE Banner Activity

CE / CME

Clinical Insights and Guidance on New Evidence and the Expanding Treatment Options for Hemophilia

Video

On-demand webcast from a workshop series on the evolving hemophilia A & B treatment landscape, including extended half-life factor and nonfactor replacement therapies, therapies that aim to restore the hemostatic balance, and gene therapies.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 05, 2023

Expiration: May 04, 2024

No longer available for credit.

Share

Faculty

Stacy E. Croteau

Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Childrens Hospital
Harvard Medical School
Boston, Massachusetts

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

This activity is provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by educational grants from Novo Nordisk and Sanofi Genzyme.

Novo Nordisk

Sanofi Genzyme

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with hemophilia.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in using novel therapeutic options for patients with hemophilia A and B.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized hemophilia A and B prophylactic strategies that optimize adherence and clinical outcomes

  • Apply recent safety and efficacy data for newer factor replacement therapies in hemophilia A and B to clinical practice

  • Integrate the most recent data on currently available and emerging nonfactor prophylaxis into clinical practice for patients with hemophilia A and B

  • Discuss with patients the mechanisms of action, available data, along with benefits and potential risks of emerging gene therapies in hemophilia A and B care

  • Identify patients with hemophilia A or B who may be eligible for enrollment on a clinical trial investigating agents that target anticoagulant pathways or next-generation bispecific antibodies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Childrens Hospital
Harvard Medical School
Boston, Massachusetts

Stacy E. Croteau, MD, MMS: researcher: Genentech, Novo Nordisk, Octapharma, Pfizer, Spark; consultant: CSL-Behring, Genentech, Novo Nordisk, Shire.

Primary Author

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy Young, MD: consultant/advisor/speaker: Bayer, BioMarin, CSL Behring, Genentech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, and Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 05, 2023, through May 04, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.

2. Read the target audience, learning objectives, and faculty disclosures.

3. View and study the content in its entirety.

4. Submit answers to the posttest questions and evaluation questions online.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours. 

Continuing Pharmacy Education


CCO designates this continuing education activity for 1.00 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-128-H01-P 

Type of Activity: Application 

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.